|
EP3532039A1
|
|
Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
|
|
WO2017123549A1
|
|
Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids
|
|
US2017106011A1
|
|
Methods of treating traumatic brain injury and sequelae
|
|
AU2016234916A1
|
|
Treatment of myelosuppression
|
|
GB201611533D0
|
|
2-O, 3-O-desulfated heparin derivatives with reduced content of reactive saccharides
|
|
EP3258941A1
|
|
Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
|
|
US2016243168A1
|
|
Adoptive cell transfer methods
|
|
WO2015142924A1
|
|
Multivalent cation formulations of partially desulfated heparins
|
|
KR20160101898A
|
|
Methods of treating and preventing radiation damage
|
|
EP2846809A1
|
|
Treatment of myelosuppression
|
